{
  "module": "responder_subgroup_sim",
  "blueprint_id": "ITEPEKIMAB-χ1",
  "description": "Simulates SEI-projected response likelihood across COPD subgroups. Identifies optimal responder clusters for SEI-stratified trial design.",
  "stratification_variables": [
    "IL-33 expression level",
    "Peripheral eosinophil count",
    "Epithelial damage index (EDI)",
    "Th2/Th17 dominance score",
    "Prior exacerbation history (3-year window)",
    "Baseline lung repair biomarker panel"
  ],
  "simulated_subgroups": [
    {
      "label": "IL-33-high + Eosinophilic + EDI > 0.7",
      "estimated_response_rate": 0.84,
      "confidence_score": 0.91,
      "recommendation": "Primary cohort for Phase 2 SEI trial"
    },
    {
      "label": "Moderate IL-33 + Mixed Inflammatory Profile",
      "estimated_response_rate": 0.58,
      "confidence_score": 0.78,
      "recommendation": "Secondary cohort, dose-adjusted"
    },
    {
      "label": "IL-33-low + Neutrophilic + Minimal Epithelial Injury",
      "estimated_response_rate": 0.24,
      "confidence_score": 0.63,
      "recommendation": "Exclude from early trials; monitor in late-stage"
    }
  ],
  "delivery_implication_notes": [
    "IL-33-high patients show enhanced local drug uptake with inhaled microparticle route",
    "Patients with elevated EDI respond better to MDC repair circuits",
    "Stratification by blood eosinophils is feasible for trial pre-screening"
  ],
  "sei_recommendation": {
    "trial_enrollment_filter": "Only enroll patients with IL-33 ≥ 1.3x baseline and EDI > 0.6",
    "predicted trial efficacy": "70–85% reduction in exacerbation rate at Week 52"
  }
}
